We are live on
!
Find out more
AXDX
Accelerate Diagnostics
AXDX
AXDX
Delisted
AXDX was delisted on the 14th of May, 2025.
50 hedge funds and large institutions have $18M invested in Accelerate Diagnostics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 11 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
5% more capital invested
Capital invested by funds: $17.2M → $18M (+$802K)
24% less funds holding
Funds holding: 66 → 50 (-16)
45% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 11
87% less call options, than puts
Call options by funds: $2K | Put options by funds: $15K
88% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 17
Holders
50
Holders Change
-16
Holders Change %
-24.24%
% of All Funds
0.79%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
6
Reduced
11
Closed
17
Calls
$2K
Puts
$15K
Net Calls
-$13K
Net Calls Change
+$8K
Top Buyers
| 1 |
GAM
Griffin Asset Management
New York
|
+$515K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$119K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.2K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$16K |
| 5 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$1.23K |
Top Sellers
| 1 |
CC
Cannell & Co
New York
|
-$778K |
| 2 |
Millennium Management
New York
|
-$356K |
| 3 |
AIC
AWM Investment Company
New York
|
-$281K |
| 4 |
TC
Tejara Capital
London,
United Kingdom
|
-$254K |
| 5 |
Morgan Stanley
New York
|
-$167K |
